National Health (Price and Special Patient Contribution) Amendment Determination 2020 (No. 8) (PB 97 of 2020) (Cth)
PB 97 of 2020
National Health (Price and Special Patient Contribution) Amendment Determination 2020 (No. 8)
I, Thea Connolly, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make the following Determination.
Dated 28 September 2020
THEA CONNOLLY
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health
Contents
1 Name........................................................................................................................................ 1
2 Commencement........................................................................................................................ 1
3 Authority.................................................................................................................................. 1
4 Schedules................................................................................................................................. 1
Schedule 1—Amendments 2
National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010) 2
1 Name
This instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2020 (No. 8).
This instrument may also be cited as PB 97 of 2020
2 Commencement
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
| Commencement information | ||
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. The whole of this instrument | I October 2020. | |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
3 Authority
This instrument is made under section 85B of the National Health Act 1953.
4 Schedules
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1—Amendments
National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010)
1 Schedule 1, entry for Acarbose
Omit
| Acarbose | Tablet 50 mg | Oral | Glucobay 50 | 90 | 15.51 | 17.65 |
| Tablet 100 mg | Oral | Glucobay 100 | 90 | 21.96 | 24.10 |
Substitute
| Acarbose | Tablet 100 mg | Oral | Glucobay 100 | 90 | 21.96 | 24.10 |
2 Schedule 1, after entry for Dutasteride
Insert
| Dutasteride with tamsulosin | Capsule containing dutasteride 500 micrograms with tamsulosin hydrochloride 400 micrograms | Oral | 30 | 18.29 | 21.55 |
3 Schedule 1, entry for Mirtazapine
Omit
| Mirtazapine | Tablet 30 mg | Oral | Avanza | 30 | 3.35 | 8.00 |
| Tablet 45 mg (orally disintegrating) | Oral | Remeron SolTab | 30 | 7.72 | 12.14 |
Substitute
| Mirtazapine | Tablet 30 mg | Oral | Avanza | 30 | 3.35 | 8.00 |
4 Schedule 1, entry for Olmesartan in the form Tablet containing olmesartan medoxomil 20 mg
omit from the column headed “Claimed Price”: 6.71 substitute: 7.09
5 Schedule 1, entry for Olmesartan in the form Tablet containing olmesartan medoxomil 40 mg
omit from the column headed “Claimed Price”: 11.00 substitute: 11.39
6 Schedule 1, entry for Olmesartan with hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg
(a)omit from the column headed “Determined Price”: 5.27 substitute: 4.57
(b)omit from the column headed “Claimed Price”: 6.97 substitute: 6.04
7 Schedule 1, entry for Olmesartan with hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg
(a)omit from the column headed “Determined Price”: 9.57 substitute: 8.46
(b)omit from the column headed “Claimed Price”: 11.24 substitute: 9.94
8 Schedule 1, entry for Olmesartan with hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg
(a)omit from the column headed “Determined Price”: 11.00 substitute: 9.57
(b)omit from the column headed “Claimed Price”: 12.70 substitute: 11.05
9 Schedule 1, entry for Rosuvastatin in the form Tablet 10 mg (as calcium)
(a)omit from the column headed “Determined Price”: 5.14 substitute: 3.16
(b)omit from the column headed “Claimed Price”: 7.14 substitute: 4.39
0
0
0